TwinBeech Capital’s Regenxbio RGNX Stock Holding History

TwinBeech Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,786	Closed	-$266K	–	617
2021 Q1	$266K	Buy	+7,786	New	+$332K	0.04%	397
2020 Q4	–	Sell	-9,074	Closed	-$250K	–	582
2020 Q3	$250K	Buy	+9,074	New	+$296K	0.05%	368

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TwinBeech Capital's RGNX Position: Q2 2021 in Review

TwinBeech Capital sold out of Regenxbio (RGNX) in Q2 2021, closing a stake of 7,786 shares — an estimated $266K sold.

TwinBeech Capital first reported a position in RGNX in Q3 2020 and held it in 2 quarters. The position peaked at $266K in Q1 2021. 172 funds tracked by Wall St. Rank hold RGNX as of Q2 2021.

TwinBeech Capital reported no remaining Regenxbio position as of Q2 2021 after selling out during the quarter.
TwinBeech Capital sold 7,786 Regenxbio shares in Q2 2021, an estimated $266K.
TwinBeech Capital first reported a position in Regenxbio in Q3 2020 and held it in 2 quarters.
TwinBeech Capital's Regenxbio position peaked at $266K in Q1 2021.
172 funds tracked by Wall St. Rank held Regenxbio as of Q2 2021.

Based on TwinBeech Capital's 13F filing for Q2 2021, filed 16 Aug 2021.